Table 2.
Comparison of characteristics and outcome for patients discharged with dual antiplatelet therapy vs. oral anticoagulation in addition to single or dual antiplatelet therapy
| DAPT, n = 24 | OAC + (D)APT, n = 29 | p | |
|---|---|---|---|
| Age, y (SD) | 76.0 ± 8.2 | 80.2 ± 7.2 | 0.053 |
| Female sex, % (n) | 33 (8) | 24 (7) | 0.55 |
| Median prestroke mRS (IQR) | 0 (0–1.25) | 0 (0–1) | 0.87 |
| Median NIHSS (IQR) | 14 (9–17) | 14 (9–18) | 0.96 |
| Median ASPECTS (IQR) | 9 (7–10) | 10 (8–10) | 0.30 |
| Cardiovascular risk factors, % (n) | |||
| Hypertension | 92 (22) | 90 (26) | 1.0 |
| Diabetes | 38 (9) | 14 (4) | 0.06 |
| Dyslipidemia | 54 (13) | 55 (16) | 1.0 |
| Baseline medication, % (n) | |||
| Antiplatelet therapy | 38 (9) | 21 (6) | 0.23 |
| Oral anticoagulation | 13 (3) | 48 (14) | 0.008 |
| Procedural results | |||
| IVT, % (n) | 57 (13) | 28 (8) | 0.048 |
| mTICI ≥ 2b, % (n) | 92 (22) | 100 (28) | 0.21 |
| Passages, n (IQR) | 1 (1–2) | 1 (1–2) | 0.75 |
| Median time SO to ADM (IQR) | 166 (111–200.25)# | 147 (67.5–197.5)+ | 0.70 |
| Median time LSW to ADM (IQR) | 300 (241–401.5)# | 633 (426–888)+ | 0.09 |
| Median time ADM to GRO (IQR) | 53.5 (33.25–70.75) | 53 (36–107) | 0.50 |
| Median time GRO to FLR (IQR) | 61.5 (34.5–75.75) | 54 (36–91) | 0.82 |
| Hospital stay | |||
| Malignant MCA infarction, % (n) | 0 | 3 (1) | 1.0 |
| Recurrent stroke, % (n) | 13 (3) | 17 (5) | 0.72 |
| In-stent thrombosis, % (n) | 8 (2) | 0 | 0.20 |
| ICH, % (n) | 4 (1) | 17 (5) | 0.20 |
| Median NIHSS at 24 h (IQR) | 11 (6–15) | 10 (8–17.50) | 0.82 |
| Median mRS at 24 h (IQR | 4 (4–5) | 4 (4–5) | 0.91 |
| Median discharge NIHSS (IQR) | 7.5 (3–10.5) | 7 (4–11) | 0.73 |
| Median discharge mRS (IQR) | 4 (3–4) | 4 (3–5) | 0.79 |
| Median duration of stay, d (IQR) | 9 (7–12.5) | 7.5 (6–17.25) | 0.75 |
| Outcome | |||
| Median mRS at 90 days (IQR) | 3.5 (2–6) | 3 (2–4) | 0.38 |
| mRS 0–2 at 90 days, % (n) | 36 (8) | 42 (10) | 0.77 |
| Mortality at 90 days, % (n) | 32 (7) | 4 (1) | 0.020 |
#SO was reported in 50%, LSW in 42%, no information on time of onset available in 8% (n = 2)
+SO was reported in 66%, LSW in 28%, no information on time of onset available in 7% (n = 2)
DAPT dual antiplatelet therapy; OAC oral anticoagulation; (D)APT single or dual antiplatelet therapy; ASPECTS Alberta Stroke Program Early CT Score; IQR interquartile range; NIHSS National Institutes of Health Stroke Scale; IVT, intravenous thrombolysis; mTICI modified Thrombolysis in Cerebral Infarction scale; mRS modified Rankin Scale; SO symptoms onset; LSW last seen well, ADM admission; GRO groin puncture; FLR flow restoration